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Article

Albuminuria Changes and Cardiovascular and Renal
Outcomes in Type 1 Diabetes: The DCCT/EDIC Study
Ian H. de Boer,* Xiaoyu Gao,† Patricia A. Cleary,† Ionut Bebu,† John M. Lachin, Mark E. Molitch,‡ Trevor Orchard,§
Andrew D. Paterson,| Bruce A. Perkins,¶ Michael W. Steffes,** and Bernard Zinman,†† for the Diabetes Control and
Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group

Abstract
Background and objectives In trials of people with type 2 diabetes, albuminuria reduction with renin-angiotensin
system inhibitors is associated with lower risks of cardiovascular events and CKD progression. We tested
whether progression or remission of microalbuminuria is associated with cardiovascular and renal risk in a well
characterized cohort of type 1 diabetes.
Design, setting, participants, & measurements We studied 1441 participants in the Diabetes Control and
Complications Trial/Epidemiology of Diabetes Interventions and Complications study. Albumin excretion rate
(AER) was quantiﬁed annually or biennially for up to 30 years. For each participant, albuminuria status was
deﬁned over time as normoalbuminuria (AER continuously ,30 mg/d), sustained microalbuminuria (AER,
30–299 mg/d on two consecutive visits), macroalbuminuria (AER$300 mg/d), or remitted microalbuminuria
(transition from sustained microalbuminuria to AER,30 mg/d on two consecutive visits). We tested associations
of time-updated albuminuria status with adjudicated clinical cardiovascular events, the development of reduced
GFR (,60 ml/min per 1.73 m2 on two consecutive visits), and subclinical cardiovascular disease.
Results At least one cardiovascular event occurred in 184 participants, and 98 participants developed reduced
eGFR. Compared with normoalbuminuria, sustained microalbuminuria, remitted microalbuminuria, and
macroalbuminuria were each associated with higher risk of cardiovascular events (adjusted hazard ratios [HRs]
and 95% conﬁdence intervals [95% CIs]: 1.79 [1.13 to 2.85], 2.62 [1.68 to 4.07], and 2.65 [1.68 to 4.19], respectively)
and reduced eGFR (adjusted HRs [95% CIs], 5.26 [2.43 to 11.41], 4.36 [1.80 to 10.57], and 54.35 [30.79 to 95.94],
respectively). Compared with sustained microalbuminuria, remission to normoalbuminuria was not associated
with reduced risk of cardiovascular events (adjusted HR, 1.33; 95% CI, 0.68 to 2.59) or reduced eGFR (adjusted
HR, 1.75; 95% CI, 0.56 to 5.49). Compared with normoalbuminuria, sustained microalbuminuria, remitted
microalbuminuria, and macroalbuminuria were associated with greater carotid intima-media thickness, and
macroalbuminuria was associated with a greater degree of coronary artery calciﬁcation.
Conclusions In type 1 diabetes, microalbuminuria and macroalbuminuria are associated with higher risks of
cardiovascular disease and reduced eGFR, but achieving a remission of established microalbuminuria to
normoalbuminuria does not appear to improve outcomes.
Clin J Am Soc Nephrol 11: 1969–1977, 2016. doi: 10.2215/CJN.02870316

Introduction
Albuminuria is strongly associated with the progression
of CKD as well as cardiovascular disease (CVD) (1).
However, urine albumin excretion is not static. For example, microalbuminuria (albumin excretion rate [AER]
of 30–299 mg/d) can progress to macroalbuminuria
(AER$300 mg/d) or remit to normoalbuminuria
(AER,30 mg/d), with or without renin-angiotensin
system (RAS) inhibition (2–4). Similarly, macroalbuminuria can remit to microalbuminuria and even normoalbuminuria (3).
In clinical trials, changes in albuminuria correlate
with renal and cardiovascular risk (5–8), supporting
the viewpoint that albuminuria be considered a therapeutic target in clinical care and surrogate outcome
www.cjasn.org Vol 11 November, 2016

in clinical trials (9–11). However, the predominant
evidence supporting this argument comes from trials
of people with type 2 diabetes and very high baseline
urine albumin excretion treated with RAS inhibitors.
It remains unclear whether changes in albumin are
associated with improved clinical outcomes in other
populations, at lower levels of urine albumin excretion, or outside the setting of RAS blockade.
We tested whether changes in urine albumin excretion were associated with differences in renal and
cardiovascular risk in a well characterized cohort of
type 1 diabetes. Up to 60% of patients with type 1
diabetes develop microalbuminuria, among whom
similar proportions remit to normoalbuminuria or
progress to more advanced stages of CKD (4,12). We
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hypothesized that progression and remission of microalbuminuria would be associated with higher and lower
long-term risks, respectively, of adverse cardiovascular
and renal outcomes.

Materials and Methods
Study Population
The Diabetes Control and Complications Trial (DCCT)
enrolled 1441 persons with type 1 diabetes from 1983 to
1989 to determine the effects of intensive diabetes therapy
on the long-term complications of diabetes (13). The trial
included two cohorts. The primary prevention cohort was
characterized by diabetes duration of 1–5 years, AER,40
mg/24 h, and no retinopathy by fundus photography. The
secondary intervention cohort was characterized by diabetes duration of 1–15 years, AER#200 mg/24 h, and at least
one microaneurysm in either eye (but no more than moderate
nonproliferative retinopathy). For both cohorts, serum creatinine ,1.2 mg/dl or creatinine clearance .100 ml/min per
1.73 m2 was required for eligibility.
Participants were randomly assigned to intensive diabetes therapy, aimed at lowering glucose concentrations
as close as safely possible to the normal range, or to conventional therapy, aimed at preventing symptoms of hyperglycemia and hypoglycemia. In 1994, after completion of
the DCCT, 1375 participants (96% of the surviving cohort)
agreed to participate in the Epidemiology of Diabetes
Interventions and Complications (EDIC) study. During
the EDIC study, diabetes therapy and glycemic control as
measured by hemoglobin A1c (HbA1c) became similar in
the two original DCCT treatment groups, and yearly followup has continued through the present time (14). This study
includes data from all participants collected through May 1,
2014 (EDIC study year 21).
Albuminuria
AER was measured yearly during the DCCT and every 2
years during the EDIC study. All assays were completed at
the DCCT/EDIC Central Biochemistry Laboratory. From
DCCT baseline through EDIC study year 18 (calendar year
2012), urine was collected for 4 hours during a water
diuresis and albumin was measured by ﬂuoroimmunoassay (coefﬁcient of variation, 9.4%) (15). Starting in EDIC
study year 19, spot urine samples were collected, urine
albumin was measured using an immunoturbidimetric
method, and a formula developed and validated in the
EDIC study was used to estimate AER from urine albumin
and creatinine concentrations (16).
For each participant, at the time of each urine collection,
albuminuria status could be reclassiﬁed on the basis of their
AER history into one of four mutually exclusive categories
(normoalbuminuria, sustained microalbuminuria, remitted
microalbuminuria, and macroalbuminuria), deﬁned in a
manner consistent with our prior work (Figure 1) (17).
Participants were considered to have normoalbuminuria
until they developed sustained microalbuminuria (two
consecutive study visits with AER$30 mg/d) or macroalbuminuria (AER$300 mg/d in the absence of hematuria)
(3,4). Sixty-eight participants with AER of 30–200 mg/d at
baseline and $30 mg/d at their next DCCT visit were considered to have sustained microalbuminuria starting at

Figure 1. | Transitions in albuminuria status observed during the
Diabetes Control and Complications Trial (DCCT)/Epidemiology of
Diabetes Interventions and Complications (EDIC) study. The figure
depicts the four albuminuria categories examined in primary analyses and the observed numbers of transitions between categories. Of
1441 participants included, 1373 entered the DCCT with normoalbuminuria and 68 entered the DCCT with persistent microalbuminuria. During subsequent follow-up, 355 participants with
normoalbuminuria at baseline developed persistent microalbuminuria, 171 participants with persistent microalbuminuria
regressed to persistent normoalbuminuria, and 180 participants
developed macroalbuminuria. Some participants were observed
to undergo multiple transitions in albuminuria status over time
and were included in multiple counts in the figure. AER, albumin
excretion rate.

DCCT baseline and included in all analyses. Participants
were considered to have sustained microalbuminuria
until they were observed to have two consecutive AER
values ,30 mg/d (remission to normoalbuminuria) or an
AER$300 mg/d (macroalbuminuria). Participants who remitted to normoalbuminuria could subsequently develop
and be reclassiﬁed as having sustained microalbuminuria
or macroalbuminuria. Some participants who developed
macroalbuminuria were subsequently observed to have
two AER values ,300 mg/d (remitted macroalbuminuria).
Because insufﬁcient numbers of events were observed for
participants with remitted macroalbuminuria, they were included in the macroalbuminuria group for primary analyses
but analyzed separately in secondary analyses.
Cardiovascular Outcomes
The primary study outcome, any CVD, was a composite
of the time to the ﬁrst occurrence of nonfatal myocardial
infarction or stroke, death from CVD, subclinical myocardial infarction on electrocardiography (“silent” myocardial
infarction), conﬁrmed angina, or the need for coronary artery revascularization, consistent with published DCCT/
EDIC study analyses (18). A secondary outcome, major
adverse cardiovascular event (MACE), included only the
time to the ﬁrst of nonfatal myocardial infarction or stroke
or death from CVD. CVD events were adjudicated by physician review through December 31, 2013. For secondary
subclinical outcomes, we also examined coronary artery
calcium (CAC) measured at EDIC study year 7–8 (November
22, 2000–March 21, 2003) and carotid intima-media thickness
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(IMT) measured at EDIC study year 12 (January 5, 2004–
August 17, 2005) (19,20).

analyses were performed using SAS software (version
9.4; SAS Institute, Cary, NC).

Renal Outcomes
Serum creatinine was measured with highly reproducible methods annually throughout the DCCT and EDIC
study at the DCCT/EDIC Central Biochemistry Laboratory. Most recently, results were calibrated to values
traceable to isotope dilution mass spectrometry (14). The
CKD-Epidemiology Collaboration equation was used to
estimate GFR from calibrated serum creatinine (21). Reduced GFR was deﬁned as eGFR,60 ml/min per 1.73 m2
on two consecutive study visits, the initiation of maintenance dialysis, or kidney transplantation (14).

Results

Covariates
Covariates were updated concurrently with updates in
albuminuria status over time. Use of angiotensin-converting
enzyme inhibitors and angiotensin 2 receptor blockers
were combined as use of RAS inhibitors, and use of lipidlowering medications (mostly hydroxymethyl glutaryl
coenzyme A reductase inhibitors) were combined as lipidlowering medications. Smoking status was ascertained by
questionnaire. Body mass index and BP were measured in
standardized fashions by trained research coordinators (22).
HbA1c was measured by HPLC (23). The time-weighted
updated mean HbA1c was computed up to each visit
with quarterly HbA1c values during DCCT weighted by
1/4 and annual EDIC study values by 1.
Statistical Analyses
We quantiﬁed total time at risk by albuminuria status,
with each participant able to contribute risk time to
multiple albuminuria categories. We quantiﬁed the numbers of ﬁrst cardiovascular and renal events and unadjusted incidence rates of these events by time-updated
albuminuria status. We then used Cox proportional hazards models to test associations of albuminuria status as
a time-dependent variable with time to ﬁrst CVD event.
We stratiﬁed the proportional hazards model by DCCT
treatment assignment and adjusted for covariates that
were anticipated to potentially confound the associations
of primary interest based on current understanding of
pathophysiology. Model 1 was adjusted for age, sex, and
attained duration of diabetes, and model 2 was additionally adjusted for renin-angiotensin inhibitor use, smoking,
and updated weighted mean HbA1c as time-dependent
covariates. A secondary time-to-event analysis designed to
account for duration of exposure to microalbuminuria was
restricted to participants who developed microalbuminuria or macroalbuminuria and used time since development
of microalbuminuria or macroalbuminuria (whichever occurred ﬁrst) as the unit of time.
We tested associations of albuminuria status with the
presence of CAC (Agatston score .0 versus $0) using
multivariable logistic regression and with the presence
and extent of CAC using Tobit regression (19). We used
multiple linear regression to test associations of albuminuria status with carotid IMT. We used albuminuria status
concurrent with or immediately preceding each subclinical CVD measurement as exposure for these analyses. All
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Participant Characteristics
At baseline, mean participant age was 26.9 years; mean
duration of diabetes was 5.6 years; 47% of participants
were female; 96% of participants were white; and no
participants were using RAS inhibitors (Table 1). Sustained
microalbuminuria developed in 423 participants at a mean
age of 33.9 years and a mean diabetes duration of 14.5 years.
Of the 423 participants who developed microalbuminuria,
171 remitted to normoalbuminuria and 180 progressed to
macroalbuminuria. At the time of remission or progression,
28% or 35%, respectively, were using RAS inhibitors.
Median follow-up times were as follows: after developing sustained microalbuminuria, 17.8 years (interquartile
range [IQR], 10.0–24.0 years; range, 0–29.6 years); after remission of microalbuminuria, 15.7 years (IQR, 8.2–22.1
years; range, 1.0–27.1 years); and after developing macroalbuminuria, 12.0 years (IQR, 5.8–16.9 years; range, 0–28.4
years). Among the 168 who remitted to normoalbuminuria
before a ﬁrst CVD event, 127 (75.6%) persisted in normoalbuminuria until their follow-up time was censored,
whereas 40 (23.8%) were reclassiﬁed to sustained microalbuminuria and one (0.6%) was reclassiﬁed to macroalbuminuria during follow-up.
Clinical Cardiovascular Events
During 24.6 mean years of follow-up (range, 0–30 years),
an initial cardiovascular event (any CVD) was observed in
184 participants, including 88 with a MACE. Compared
with normoalbuminuria, time-updated sustained microalbuminuria, remitted microalbuminuria, and macroalbuminuria were each associated with higher risks of any CVD
event and MACE, after adjustment for age, sex, attained
duration of diabetes, and DCCT treatment assignment:
hazard ratios (HRs) and 95% conﬁdence intervals (95%
CIs) of 1.79 (1.13 to 1.85), 2.62 (1.68 to 4.07), and 2.65
(1.68 to 4.19), respectively (Table 2). With further adjustment for RAS inhibitor use, smoking, and HbA1c, remitted
microalbuminuria and macroalbuminuria were associated
with signiﬁcantly higher risk of any CVD, but sustained
microalbuminuria was not. Neither further adjustment for
eGFR nor introduction of a 4-year time lag between assessment of albuminuria and CVD events substantially
changed these results (Supplemental Tables 1 and 2). Compared with participants with sustained microalbuminuria,
those with remission of microalbuminuria or macroalbuminuria were estimated to have higher risks of CVD
events, but these associations were not statistically significant (Table 3).
Renal Outcomes
During 25.2 mean years of follow-up (range, 0–31 years),
incident reduced eGFR was observed in 98 participants.
Compared with normoalbuminuria, time-updated sustained microalbuminuria, remission of microalbuminuria,
and particularly macroalbuminuria were each strongly associated with higher risk of reduced eGFR: HRs and 95%
CIs of 5.26 (2.43 to 11.41), 4.36 (1.80 to 10.57), and 54.35
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Table 1. Characteristics of participants in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and
Complications study at baseline and at the time that albuminuria developed, remitted, or progressed

During Follow-up
Characteristic

Age, yr
Women
White patients
DCCT treatment assignment
(intensive therapy)
Duration of diabetes, mo
RAS inhibitor use
Never
Current
Prior
Lipid-lowering
medication use
Current smoking
Body mass index, kg/m2
Systolic BP, mmHg
Diastolic BP, mmHg
Updated mean
hemoglobin A1c, %
Albumin excretion rate, mg/d
eGFR, ml/min per 1.73 m2
LDL cholesterol, mg/dl

At Baseline
(n=1441)

26.967.1
680 (47)
1390 (96)
711 (49)
67.6649.9
1441 (100)
0
0
0

Time of
Microalbuminuria
Diagnosis (n=423)

Time of
Microalbuminuria
Remission (n=171)

Time of
Macroalbuminuria
Development (n=180)

33.9611.2
175 (41)
404 (96)
167 (39)

36.7611.2
94 (55)
168 (98)
80 (47)

38.3610.2
59 (33)
166 (92)
55 (30)

173.6686.7

222.8696.9

224.5680.4

358 (85)
52 (12)
13 (3)
43 (10)

266 (18)
23.562.8
114.5611.4
73.068.5
8.961.6

109 (26)
25.964.3
121.7614.2
76.868.8
9.261.4

11.5 (7.2, 18.7)
126.1614.2
109.7629.1

46.1 (36.0, 69.1)
117.8618.2
115.8630.7

116 (68)
48 (28)
7 (4)
33 (19)

108 (60)
63 (35)
9 (5)
31 (17)

37 (22)
27.265.3
119.5614.8
73.769.3
8.561.3

49 (27)
27.064.5
131.9617.3
81.3610.1
9.761.3

14.4 (11.5, 21.6)
110.5618.1
111.8632.7

534.2 (393.1, 796.3)
106.0622.4
125.6635.8

Data are mean6SD or n (%), except for albumin excretion rate, which is summarized as median (25th percentile, 75th percentile). DCCT,
Diabetes Control and Complications Trial; RAS, renin-angiotensin system.

(30.79 to 95.94), respectively (Table 2). Among participants
who developed microalbuminuria or macroalbuminuria,
remission of microalbuminuria was associated with a nonsigniﬁcantly higher risk of reduced eGFR compared with
sustained microalbuminuria, whereas progression to macroalbuminuria was signiﬁcantly associated with higher
risk of reduced eGFR (Table 3). When a 4-year time lag
was introduced between assessment of albuminuria status
and assessment of eGFR, remitted microalbuminuria was
not signiﬁcantly associated with risk of reduced eGFR
(Supplemental Table 2).
Remission of Macroalbuminuria
Among participants who developed macroalbuminuria
and subsequently remitted to persistent AER,300 mg/d,
only seven developed a CVD event (including six with a
MACE) and eight developed reduced eGFR (Supplemental
Table 3). Compared with participants with normoalbuminuria, those with remitted macroalbuminuria had higher risks
of CVD events and reduced eGFR. Compared with participants with sustained macroalbuminuria, those with remitted
macroalbuminuria appeared to have similar risk of CVD
events, with widely overlapping 95% CIs due to low numbers of event, but substantially lower risk of reduced eGFR.
Subclinical CVD
CAC was present in 339 of 1156 participants (29.3%).
Macroalbuminuria was associated with higher risk of CAC

compared with normoalbuminuria, but this was signiﬁcant
only in minimally adjusted models (Supplemental Table 4,
Tables 4 and 5). Neither sustained nor remitted microalbuminuria was associated with CAC. Compared with normoalbuminuria, sustained microalbuminuria, remitted
microalbuminuria, and macroalbuminuria were each associated with greater common carotid IMT.

Discussion

In this cohort study of type 1 diabetes spanning .30
years, the development of microalbuminuria or macroalbuminuria was associated with higher risks of clinical
CVD and renal events, as expected. However, contrary
to our hypothesis, remission from microalbuminuria to
normoalbuminuria was not associated with reduced
CVD or renal risk compared with sustained microalbuminuria. The lack of association of microalbuminuria remission with lower CVD and renal risk was robust in analyses
adjusting for use of RAS inhibitors and accounting for time
since microalbuminuria onset. Similarly, remission of microalbuminuria to normoalbuminuria was not associated
with reduced subclinical CVD, quantiﬁed as CAC or carotid IMT.
Albuminuria has been consistently associated with
higher CVD and renal risk across multiple cohorts with
type 1 diabetes, including the DCCT/EDIC study, as well
as cohorts with type 2 diabetes and the general population (1,18,24–26). Furthermore, albuminuria and other

27,310
2882
2089
1899
27,773
2975
2216
2052
27,292
2976
2246
1710

48
11
11
18
19
10
7
62

Person-Years
at Risk

109
23
27
25

Events, n

1.1
5.6
5.8
67.6

2.7
6.2
9.2
17.1

6.3
13.2
23.9
25.5

Incidence Rate (per
1000 Person-Years)

1 (reference)
5.26 (2.43 to 11.41)a
4.36 (1.80 to 10.57)a
54.35 (30.79 to 95.94)a

1 (reference)
2.01 (1.03 to 3.90)a
2.28 (1.15 to 4.53)a
4.19 (2.34 to 7.52)a

1 (reference)
1.79 (1.13 to 2.85)a
2.62 (1.68 to 4.07)a
2.65 (1.68 to 4.19)a

HR (95% CI)

Model 1

,0.001
0.001
,0.001

0.04
0.02
,0.001

0.01
,0.001
,0.001

P Value

1 (reference)
2.68 (1.19 to 6.03)a
3.18 (1.31 to 7.77)
25.50 (13.42 to 48.46)a

1 (reference)
1.41 (0.70 to 2.81)
1.88 (0.94 to 3.76)
2.96 (1.54 to 5.67)a

1 (reference)
1.31 (0.81 to 2.12)
2.25 (1.44 to 3.51)a
1.76 (1.06 to 2.91)a

HR (95% CI)

Model 2

0.02
0.01
,0.001

0.34
0.07
0.001

0.28
,0.001
0.03

P Value

In model 1, the proportional hazards model was stratiﬁed by Diabetes Control and Complications Trial (DCCT) treatment assignment and adjusted for age, sex, and attained duration of
diabetes. In model 2, the proportional hazards model was stratiﬁed by DCCT treatment assignment, adjusted for age and sex as ﬁxed covariates, and adjusted for attained duration of diabetes,
renin-angiotensin inhibitor use, smoking, and updated weighted mean hemoglobin A1c as time-dependent covariates. HR, hazard ratio; 95% CI, 95% conﬁdence interval.
a
Results with P,0.05.

All cardiovascular events
Normoalbuminuria
Sustained microalbuminuria
Remitted microalbuminuria
Macroalbuminuria
Major adverse cardiac events
Normoalbuminuria
Sustained microalbuminuria
Remitted microalbuminuria
Macroalbuminuria
Sustained eGFR<60 ml/min per 1.73 m2
Normoalbuminuria
Sustained microalbuminuria
Remitted microalbuminuria
Macroalbuminuria

Variable

Table 2. Associations of time-updated albuminuria status with cardiovascular and renal events in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and
Complications study
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Table 3. Associations of albuminuria status with cardiovascular and renal events among participants who developed
microalbuminuria

Model 1

Events, n

Variable
All cardiovascular events
Sustained microalbuminuria
Remitted microalbuminuria
Macroalbuminuria
Major adverse cardiac events
Sustained microalbuminuria
Remitted microalbuminuria
Macroalbuminuria
Sustained eGFR<60 ml/min per 1.73 m2
Sustained microalbuminuria
Remitted microalbuminuria
Macroalbuminuria

HR (95% CI)

Model 2
P Value

HR (95% CI)

P Value

23
27
25

1 (reference)
1.33 (0.68 to 2.59)
1.46 (0.76 to 2.82)

0.40
0.26

1 (reference)
1.69 (0.86 to 3.32)
1.05 (0.54 to 2.08)

0.13
0.88

11
11
18

1 (reference)
0.89 (0.34 to 2.33)
1.63 (0.70 to 3.82)

0.81
0.26

1 (reference)
1.06 (0.41 to 2.75)
1.31 (0.54 to 3.15)

0.90
0.55

10
7
62

1 (reference)
1.75 (0.56 to 5.49)
5.07 (2.36 to 10.90)a

0.34
,0.001

1 (reference)
2.21 (0.70 to 7.00)
5.11 (2.33 to 11.22)a

0.18
,0.001

In this time-to-event model, time is evaluated since the development of microalbuminuria or macroalbuminuria (whichever occurred
ﬁrst). In model 1, the proportional hazards model was stratiﬁed by Diabetes Control and Complications Trial (DCCT) treatment assignment and adjusted for age, sex, and attained duration of diabetes. In model 2, the proportional hazards model was stratiﬁed by
DCCT treatment assignment, adjusted for age and sex as ﬁxed covariates, and adjusted for attained duration of diabetes, renin-angiotensin inhibitor use, smoking, and updated weighted mean hemoglobin A1c as time-dependent covariates. HR, hazard ratio; 95%
CI, 95% conﬁdence interval.
a
Results with P,0.05.

manifestations of diabetic kidney disease accounted statistically for all the excess mortality in two large type 1 diabetes cohorts (23,24). Our observed associations of
microalbuminuria and macroalbuminuria with higher
risks of clinical and subclinical CVD as well as reduced
eGFR are consistent with these reports and support the
concept that preventing albuminuria may help improve
long-term health in type 1 diabetes.
Once developed, microalbuminuria is known to commonly regress to normoalbuminuria, a phenomenon documented ﬁrst and most clearly in type 1 diabetes (2–4). In the
present study, we conﬁrmed frequent remission from microalbuminuria to normoalbuminuria using standardized,

longitudinal measurements of AER. We required that microalbuminuria and normoalbuminuria be persistent over
time (each present on two consecutive study visits spanning at least 1–2 years), generating conﬁdence that we observed true changes in AER status. As previously reported,
remission to normoalbuminuria occurred both with and
without RAS inhibitor treatment (4).
The new ﬁnding in this study is that remission from
microalbuminuria to normoalbuminuria was not associated with reduced risk of subsequent CVD or renal events.
We were concerned that the lack of improved outcomes
with remission to normoalbuminuria may be due to
confounding by duration of preceding microalbuminuria.

Table 4. Association of albuminuria status with subclinical cardiovascular disease (coronary artery calcium)

Variable

Normoalbuminuria
Sustained
microalbuminuria
Remitted
microalbuminuria
Macroalbuminuria

Model 1

Model 2

Patients
Evaluated, n

Patients
with CAC,
n (%)

Adjusted
OR (95% CI)

P Value

Adjusted
OR (95% CI)

P Value

872
102

237 (27)
32 (31)

1 (reference)
1.12 (0.68 to 1.86)

0.28

1 (reference)
0.90 (0.53 to 1.53)

0.26

94

31 (33)

1.47 (0.86. 2.49)

0.82

1.24 (0.72 to 2.15)

0.66

88

39 (44)

2.32 (1.37 to 3.92)a

0.01

1.47 (0.81 to 2.66)

0.24

Model 1 is adjusted for age, sex, and attained duration of diabetes, and Diabetes Control and Complications Trial (DCCT) treatment
assignment, plus scan site for coronary artery calcium or reader and machine type for carotid intima-media thickness. Model 2 is
adjusted for age, sex, DCCT treatment assignment, attained duration of diabetes, renin-angiotensin inhibitor use, smoking, and updated mean hemoglobin A1c, plus scan site for coronary artery calcium or reader and machine type for carotid intima-media thickness.
CAC, coronary artery calcium; OR, odds ratio; 95% CI, 95% conﬁdence interval.
a
Results with P,0.05.
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Table 5. Association of albuminuria status with subclinical cardiovascular disease (common carotid intima-media thickness)

Model 1
Variable

Normoalbuminuria
Sustained
microalbuminuria
Remitted
microalbuminuria
Macroalbuminuria

Model 2

Patients
Evaluated, n

Mean
IMT6SD, mm

Adjusted
Difference
(95% CI), mm

P Value

Adjusted
Difference
(SEM), mm

P Value

821
91

0.6760.12
0.7460.17

0 (reference)
0.06 (0.04 to 0.09)a

,0.001

0 (reference)
0.05 (0.02–0.08)a

,0.001

105

0.6860.14

0.03 (0.01 to 0.01)a

0.02

0.03 (0.00–0.05)

0.06

94

0.7460.19

0.07 (0.05 to 0.1)a

,0.001

0.06 (0.03–0.09)a

,0.001

Model 1 is adjusted for age, sex, and attained duration of diabetes, and Diabetes Control and Complications Trial (DCCT) treatment
assignment, plus scan site for coronary artery calcium or reader and machine type for carotid intima-media thickness. Model 2 is
adjusted for age, sex, DCCT treatment assignment, attained duration of diabetes, renin-angiotensin inhibitor use, smoking, and updated mean hemoglobin A1c, plus scan site for coronary artery calcium or reader and machine type for carotid intima-media thickness
(IMT). 95% CI, 95% conﬁdence interval
a
Results with P,0.05.

However, results were robust in sensitivity analyses using
microalbuminuria onset as the beginning of time at risk.
Incidence rates of cardiovascular events were actually
higher among participants with remitted microalbuminuria
than those with sustained microalbuminuria. However, this
comparison was made using small numbers of events, and
differences were not signiﬁcant in adjusted analyses. Our
data therefore suggest that remission of microalbuminuria
to normoalbuminuria is associated with neither higher nor
lower risk of cardiovascular or renal events in type 1
diabetes. Similar results were observed in analyses of
subclinical CVD, which had substantially more power:
Remission of microalbuminuria to normoalbuminuria was
associated with neither higher nor lower CAC or carotid
IMT.
Our results suggest that the manner through which
albuminuria is reduced or the albuminuria range over
which reduction occurs may affect the association of
changes in albuminuria with CVD and renal risk. Most
participants who remitted from microalbuminuria to normoalbuminuria in our study did so without the use of RAS
inhibitors, whereas prior studies assessing the health
impact of changes in albuminuria have focused on albuminuria changes induced by RAS blockade (5–8). In addition,
we primarily assessed remission from microalbuminuria to
normoalbuminuria, whereas prior studies assessing the
health impact of changes in albuminuria have often focused
on populations with higher levels of baseline albuminuria
(8). For example, in the Reduction in End Points in Noninsulin-Dependent Diabetes Mellitus with the Angiotensin II
Antagonist Losartan study, all participants had macroalbuminuria at baseline, and RAS inhibitor–induced reductions
in albuminuria were associated with lower subsequent CVD
and renal risk (5,6). Interestingly, in our study, associations
of macroalbuminuria with reduced eGFR were very strong,
consistent with prior DCCT/EDIC reports (14). Moreover,
regression of macroalbuminuria to AER,300 mg/d was
associated with reduced risk of reduced eGFR compared
with sustained macroalbuminuria, and regression of microalbuminuria appeared to be associated with lower risk

of reduced eGFR compared with sustained microalbuminuria, when a 4-year lag time was introduced. These results conﬁrm dose-response relationships between
established albuminuria and GFR loss and are more consistent with prior studies evaluating albuminuria reductions starting from the macroalbuminuric range.
Strengths of our study include the long period of time
over which to ascertain AER status and subsequent
cardiovascular and renal outcomes, the frequent and
standardized assessment of AER, and the evaluation of
complementary clinical CVD events, subclinical CVD
outcomes, and eGFR outcomes. Limitations include an
inability to fully ascertain the cause of remission from
microalbuminuria to normoalbuminuria (or its absence) and
the relatively small number of observed clinical events. By
design, our data do not directly evaluate the effects of any
treatment on albuminuria reduction or related cardiovascular or renal risk, nor do they address whether treatmentinduced changes in albuminuria are suitable as surrogate
end points in clinical trials.
In conclusion, our results conﬁrm the associations of the
onset of microalbuminuria and macroalbuminuria with
adverse cardiovascular and renal outcomes in type 1 diabetes. This supports the general practice of preventing the
development of microalbuminuria through such interventions as intensive glycemic control and preventing progression of microalbuminuria to macroalbuminuria through such
interventions as RAS inhibition and BP control. However,
remission of established microalbuminuria to normoalbuminuria was not associated with improved cardiovascular or
renal outcomes.
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VP, Rosengård-Bärlund M, Saraheimo M, Hietala K, Heikkilä O,
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